US Stock MarketDetailed Quotes
TGTX TG Therapeutics
- 34.550
- +3.400+10.91%
Close Nov 21 16:00 ET
- 34.740
- +0.190+0.55%
Post 19:17 ET
5.38BMarket Cap-345500P/E (TTM)
36.400High31.360Low5.84MVolume31.610Open31.150Pre Close201.24MTurnover4.01%Turnover Ratio383.89P/E (Static)155.67MShares36.50052wk High28.00P/B5.03BFloat Cap12.30052wk Low--Dividend TTM145.70MShs Float149414.006Historical High--Div YieldTTM16.18%Amplitude0.956Historical Low34.466Avg Price1Lot Size
TG Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -114.58%-12.21M | 113.18%5.54M | 86.30%-8.21M | 82.17%-31.41M | 44.66%-13.21M | 342.66%83.7M | 14.48%-42.01M | 12.79%-59.9M | 40.41%-176.17M | 72.53%-23.87M |
| Net income from continuing operations | -96.59%3.88M | 114.45%6.88M | 72.71%-10.71M | 106.39%12.67M | 72.80%-14.42M | 418.08%113.93M | -17.52%-47.61M | 43.15%-39.23M | 43.02%-198.34M | 43.22%-52.99M |
| Depreciation and amortization | -49.21%64K | -15.29%72K | -32.23%82K | -17.86%423K | -27.78%91K | -2.33%126K | -35.11%85K | -6.20%121K | 4.25%515K | -5.26%126K |
| Other non cash items | 31.39%1.04M | -10.75%1.2M | 0.00%1.01M | 0.25%4.45M | 19.80%1.31M | -53.17%790K | 93.08%1.34M | 4.66%1.01M | 85.28%4.44M | 83.58%1.1M |
| Change In working capital | 20.65%-31.83M | -30.44%-10.67M | 78.58%-6.07M | -5,040.19%-84.66M | -147.33%-8.05M | -447.47%-40.11M | 2.85%-8.18M | -871.66%-28.32M | 86.52%-1.65M | 294.33%17.01M |
| -Change in receivables | -47.09%-32.12M | -110.20%-18.63M | -61.07%-13.89M | -3,778.40%-51.09M | ---11.77M | -24,913.64%-21.84M | -1,188.57%-8.86M | -1,870.64%-8.62M | 200.00%1.39M | --0 |
| -Change in inventory | -0.16%-2.54M | -29.82%-2.56M | -37.17%-36.93M | ---36.94M | ---5.51M | ---2.54M | ---1.97M | ---26.92M | --0 | --0 |
| -Change in payables and accrued expense | 154.25%11.67M | -3.44%8.96M | 308.01%40.22M | 101.74%192K | -84.39%2.56M | -253.69%-21.51M | 182.95%9.28M | 196.93%9.86M | -168.85%-11.01M | 321.07%16.43M |
| -Change in other current assets | -2,339.18%-25.59M | 115.69%1.05M | 156.81%1.49M | -134.60%-2.83M | 2,122.42%7.53M | -394.81%-1.05M | -616.83%-6.69M | -138.81%-2.62M | 196.16%8.18M | 127.06%339K |
| -Change in other current liabilities | -1,388.89%-1.39M | -87.27%14K | 9,280.77%2.44M | 645.45%300K | -80.21%56K | 109.97%108K | -84.24%110K | -44.68%26K | 99.70%-55K | 102.49%283K |
| -Change in other working capital | 170.28%18.14M | 1,410.53%498K | 1,684.21%602K | 3,857.24%5.71M | -2,336.84%-926K | 17,765.79%6.71M | 0.00%-38K | 0.00%-38K | 0.00%-152K | 0.00%-38K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -114.58%-12.21M | 113.18%5.54M | 86.30%-8.21M | 82.17%-31.41M | 44.66%-13.21M | 342.66%83.7M | 14.48%-42.01M | 12.79%-59.9M | 40.41%-176.17M | 72.53%-23.87M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 69.12%-9.33M | -94.21%1.77M | -50.05%-9.26M | -153.09%-50.65M | -375.09%-44.76M | -911.00%-30.23M | 193.87%30.5M | 85.88%-6.17M | -5,928.01%-20.01M | 394.80%16.27M |
| Net PPE purchase and sale | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- | 96.51%-14K | 96.25%-3K |
| Net investment purchase and sale | 69.20%-9.31M | -94.21%1.77M | -50.05%-9.26M | -153.27%-50.65M | -375.04%-44.76M | -912.36%-30.23M | 193.87%30.5M | 85.87%-6.17M | -29,084.06%-20M | 383.14%16.27M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 69.12%-9.33M | -94.21%1.77M | -50.05%-9.26M | -153.09%-50.65M | -375.09%-44.76M | -911.00%-30.23M | 193.87%30.5M | 85.88%-6.17M | -5,928.01%-20.01M | 394.80%16.27M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 31,836.82%134.45M | -99.71%135K | -99.96%10K | 18,694.63%72.71M | -102.04%-1K | 53.09%421K | 34,749.63%47.05M | 3,069.18%25.24M | -100.94%-391K | -99.91%49K |
| Net issuance payments of debt | --137.26M | ---- | ---- | 2,664.10%25M | --0 | --0 | --0 | 2,664.10%25M | -102.44%-975K | --0 |
| Net common stock issuance | -215,000.00%-2.15M | ---- | ---- | --46.3M | ---1K | --1K | ---- | ---- | --0 | --0 |
| Proceeds from stock option exercised by employees | -52.62%199K | -82.02%135K | -97.25%10K | 162.67%1.53M | --0 | 52.73%420K | 456.30%751K | 190.40%363K | 170.37%584K | --49K |
| Net other financing activities | ---- | ---- | ---- | ---125K | --0 | ---- | ---- | ---125K | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 31,836.82%134.45M | -99.71%135K | -99.96%10K | 18,694.63%72.71M | -102.04%-1K | 53.09%421K | 34,749.63%47.05M | 3,069.18%25.24M | -100.94%-391K | -99.91%49K |
| Net cash flow | ||||||||||
| Beginning cash position | -14.33%84.2M | 22.35%76.77M | -9.04%94.22M | -65.49%103.58M | 36.94%152.18M | -33.74%98.29M | -66.44%62.75M | -65.49%103.58M | -45.89%300.15M | -66.10%111.13M |
| Current changes in cash | 109.51%112.92M | -79.08%7.44M | 57.26%-17.45M | 95.24%-9.36M | -667.56%-57.97M | 244.84%53.9M | 192.08%35.54M | 63.93%-40.83M | 22.77%-196.57M | 72.66%-7.55M |
| End cash Position | 29.53%197.12M | -14.33%84.2M | 22.35%76.77M | -9.04%94.22M | -9.04%94.22M | 36.94%152.18M | -33.74%98.29M | -66.44%62.75M | -65.49%103.58M | -65.49%103.58M |
| Free cash flow | -114.61%-12.23M | 113.18%5.54M | 86.30%-8.21M | 82.17%-31.41M | 44.67%-13.21M | 342.63%83.7M | 14.48%-42.01M | 12.80%-59.9M | 40.49%-176.18M | 72.56%-23.87M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data